Scribe Therapeutics Inc.

Scribe Therapeutics Inc. financial statements

Scribe Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

FY2025

RevenueUSD 51.17MEODHD
Net income−USD 21.81MEODHD
Cash and equivalentsUSD 12.8MEODHD
Total debtUSD 41.43MEODHD

Scribe Therapeutics Inc. financials on 6ix · Scribe Therapeutics Inc. on 6ix